Are we over-treating with checkpoint inhibitors?

Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using...

Descripción completa

Detalles Bibliográficos
Autores principales: Danson, Sarah, Hook, Jane, Marshall, Helen, Smith, Alexandra, Bell, Sue, Rodwell, Simon, Corrie, Pippa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889152/
https://www.ncbi.nlm.nih.gov/pubmed/31527686
http://dx.doi.org/10.1038/s41416-019-0570-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889152/
https://www.ncbi.nlm.nih.gov/pubmed/31527686
http://dx.doi.org/10.1038/s41416-019-0570-y

Ejemplares similares